BGLC vs STE · rev $9.5M vs P/E 25, rev $5.46B
BioNexus Gene Lab Corp Common stock (BGLC) versus STERIS plc (STE) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
STERIS plc (STE) is a medical devices company listed on NYSE.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
Latest reported STE revenue for 2025-03-31 was $5.46B. Net income was $616.1M. Revenue was up 284.6% from 2024-03-31 to 2025-03-31. STE currently screens at market cap $19.43B and trailing P/E 25.1.
BGLC currently screens at market cap $6.1M. STE currently screens at market cap $19.43B and trailing P/E 25.1.
Not investment advice. Open the BGLC and STE stock pages for the full models.
Not investment advice.